http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Invitae Reports Third Quarter 2023 Financial Results
-
InVitae (NVTA) Launches Enhanced Chemistry of MRD Test
-
Invitae Launches Enhanced Chemistry of MRD Test to Better Serve Biopharmaceutical Clinical and Research Partnerships
-
Invitae to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
-
Landmark Study Reveals Magnitude of Uncertain Results in Clinical Genetic Testing for Hereditary Disease, Points to Evidence-Based Solutions to Reach Definitive Results
-
InVitae (NVTA) Appoints David Sholehvar as COO
-
Invitae Appoints Dr. David Sholehvar as Chief Operating Officer
-
Rural Hospital System Demonstrates the Clinical Benefits of Implementing Universal Hereditary Cancer Testing in Patients with Breast Cancer
-
Invitae to Present Data at the National Society of Genetic Counselors 42nd Annual Conference That Supports Advancements in Medical Genomics
-
InVitae's (NVTA) Common Hereditary Cancers Panel Receives FDA Market Authorization
-
Invitae's Common Hereditary Cancers Panel Receives FDA Market Authorization
-
InVitae (NVTA) Appoints Ana Schrank as CFO
-
Invitae Announces Appointment of Finance Veteran Ana Schrank as CFO
-
InVitae (NVTA) Receives NYSE Non-compliance Notice
-
Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard
-
InVitae (NVTA) Appoints Robert Guigley as Chief Commercial Officer
-
Invitae Hires Industry Veteran Robert Guigley as Chief Commercial Officer
-
InVitae (NVTA) Says Clinical Trial Results Support Genetic Testing of All Patients with Prostate Cancer
-
Clinical Trial Results Support Genetic Testing of All Patients with Prostate Cancer
-
InVitae (NVTA) Announces Selection of Finance Executive Robert Dickey as Interim CFO
-
Invitae Announces Selection of Finance Executive Robert Dickey as Interim CFO
-
Invitae Reports Second Quarter 2023 Financial Results
-
Invitae to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
-
Altoida Appoints Marc Jones as Chief Executive Officer
-
Invitae to Present at the William Blair 43rd Annual Growth Stock Conference
-
New Research Insights to be Presented by Invitae at the 2023 ASCO Annual Meeting Reinforce the Critical Role of Germline Genetic Testing in Oncology
-
Invitae Announces CFO Transition and Selection of Veteran Finance Executive Christine Gorjanc as Interim CFO
-
InVitae (NVTA) to Appeal Trial Verdict Against Natera (NTRA)
-
Invitae to Appeal Trial Verdict
-
Invitae Reports First Quarter 2023 Financial Results
-
Invitae to Announce First Quarter 2023 Financial Results on Tuesday, May 9, 2023
-
Invitae Publishes Annual Environmental, Social and Governance (ESG) Report
-
InVitae (NVTA) Reports New Publication Showing Circulating Tumor DNA (ctDNA) Can Predict and Detect Cancer Recurrence Earlier
-
New Study Findings Published in Nature Show Circulating Tumor DNA (ctDNA) Can Predict and Detect Cancer Recurrence Earlier In Non-Small Cell Lung Cancer
-
InVitae (NVTA) and Deerfield Management Partner to Create Novel Therapeutics for Rare Diseases
-
Invitae and Deerfield Management Partner to Create Novel Therapeutics for Rare Diseases
-
Invitae Announces Partnership with Epic to Streamline Genetic Testing
-
InVitae (NVTA) Appoints Dr. W. Michael Korn as Chief Medical Officer for Oncology
-
Invitae Appoints Dr. W. Michael Korn as Chief Medical Officer for Oncology
-
Invitae to Present Data at The American Clinical Genetics Meeting 2023 That Supports Removing Barriers to Genetic Testing
-
InVitae's (NVTA) PCM Assay for Minimal Residual Disease Receives First Commercial Coverage
-
Invitae's PCM Assay for Minimal Residual Disease Receives its First Commercial Coverage
-
Invitae to Present at the TD Cowen 43rd Annual Health Care Conference
-
Invitae Announces Convertible Notes and Share Exchange and New Convertible Notes Issuance
-
Invitae Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Company Updates
-
InVitae (NVTA) Appoints William H. Osborne to its Board
-
Invitae Appoints William H. Osborne to its Board of Directors
-
Invitae to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
InVitae (NVTA) Sells ArcherDX Next Generation Sequencing Research Assays to Integrated DNA Technologies
-
Integrated DNA Technologies Acquires ArcherDX Next Generation Sequencing Research Assays from Invitae Corporation
